Tag Archives: regulatory affairs

How Good for UK Pharma is the European Union?

As the United Kingdom debate about whether to stay in the European Union becomes more bitter and intense, an insight into how EU membership impacts on medicines and pharmaceuticals has appeared from a British politician who was until recently the UK Government Adviser on Life Sciences, George Freeman. His view—which is less than rosy—is worth […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | 1 Comment

FDA Rolls Out Social Media Guidance — Slowly

Pharma marketers have been clamoring for clear advice from the Food and Drug Administration on how to accommodate established rules governing drug promotion to today’s world of internet communications and social messaging. Now, a guidance from the agency’s Office of Prescription Drug Promotion (OPDP) —and its counterparts for biologics and animal drugs — outlines agency […]
Posted in multimedia, Regulatory, social media | Also tagged , | Leave a comment

"Sunshine" Just the Tip of the Iceberg: Pharma and Full Disclosure

“Sunshine” Just the Tip of the Iceberg: Full Disclosure for Pharma:??There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices, writes Jill Wechsler. Although recent legislation and regulations have greatly expanded the range of information that pharmaceutical companies have to unveil to the public, there’s an […]
Posted in Guest Blog, healthcare, Op-Ed, pricing, Regulatory, Safety, Strategy | Also tagged , , , | 1 Comment

Paul Ryan and Pharma: The Inside Story

by Tom Norton Well, we certainly have a presidential campaign now, don’t we? Good grief. Since Rep. Paul Ryan was named the Republican VP candidate last week, all hell has broken loose!  Given the intensity of the last few days, you’d think the election was tomorrow… And at some point, you do have to ask […]
Posted in FDA, Guest Blog, healthcare, Op-Ed | Also tagged , , , , | 3 Comments

US Mid-Term Elections: What It Means for Pharma

Daily News Nugget US Mid-Term Elections:  What it Means for Pharma Drink up, even if it’s  only old wine in new bottles… Yesterday’s mid-term congressional poll barely changes the stakes for pharma in its pursuit of its US legislative and regulatory agenda.    The key message coming out of the results is stalemate on the […]
Posted in Op-Ed, Regulatory | Also tagged , , , , , , | 3 Comments
  • Categories

  • Meta